logo dark logo light logo
  • About Us
  • Our Science
  • Clinical Program
    • Expanded Access Policy
  • Careers
  • News
Mobile Logo
  • About Us
  • Our Science
  • Clinical Program
    • Expanded Access Policy
  • Careers
  • News
Sep 26
Kate Morreale
Mythic News, Press Releases

Mythic Therapeutics Receives FDA Fast Track Designation for MYTX-011 for Patients with Non-Small Cell Lung Cancer (NSCLC) with cMET Overexpression

This designation encompasses NSCLC patients with any level of cMET overexpression, including low and intermediate, and potentially accelerates the path

0 Comments
Like
Sep 19
Kate Morreale
Mythic News, Press Releases

Mythic Therapeutics to Present New Preclinical Data on MYTX-011, Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Presentation to highlight the potential of MYTX-011 as a therapeutic candidate for treating a broader range of cMET-positive non-small cell

0 Comments
Like
May 25
Kate Morreale
Mythic News, Press Releases

Mythic Therapeutics Presents Trial in Progress Poster on Investigational cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 at American Society of Clinical Oncology (ASCO) Annual Meeting

The Phase 1 KisMET-01 clinical trial enrolls patients with locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC) Waltham, Mass.,

0 Comments
Like
Apr 18
Kate Morreale
Mythic News, Press Releases

Mythic Therapeutics Presents Preclinical Data on Investigational cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 at American Association for Cancer Research (AACR) Annual Meeting

VIEW THE POSTER

0 Comments
Like
Apr 4
Kate Morreale
Mythic News, Press Releases

Mythic Therapeutics Announces First Subject Dosed in Phase 1 KisMET-01 Clinical Trial of cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

MYTX-011 incorporates Mythic’s FateControl™ technology, which holds the potential to dramatically improve ADC efficacy, thereby expanding the number of NSCLC

0 Comments
Like
Sep 27
Kate Morreale
Mythic News, Press Releases

Gilles Gallant, BPharm, PhD, FOPQ, Receives the George R. Pettit Individual Input to the Field Award for 2022

Waltham, Mass., September 27, 2022 (BUSINESS WIRE) -- Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based

0 Comments
Like
Aug 23
Kate Morreale
Mythic News, Press Releases

Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer

Waltham, Mass., August 23 2022 (BUSINESS WIRE) -- Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based

0 Comments
Like
Dec 14
Mythic Author
Mythic News, Press Releases

Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing

  Mythic’s FateControl™ technology holds the potential to dramatically improve the therapeutic index of ADCs, independent of the linker and payload Series

Like
© Mythic Therapeutics. All rights reserved.  100 Beaver Street, Waltham, MA 02453 USA  Contact Us
Web Design: Someone Creative